Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Boehringer’s BIBF 1120 as Effective as Bevacizumab in Patients

Sept. 27 (Bloomberg) -- Boehringer Ingelheim’s BIBF 1120 in patients with metastatic colorectal cancer is as effective as bevacizumab with less serious adverse events, results from a Phase I/II study showed, the company said in an e-mailed statement today.

Link to Company News:{BING GR <Equity> CN <GO>}

To contact the editor responsible for this story: Rajiv Sekhri at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.